Objectives: This study aims to compare the effectiveness of desloratadine monotherapy and desloratadine plus montelukast combination therapy on quality of life in patients with persistent allergic rhinitis.
Allergic rhinitis (AR) is the most common atopic disorder affecting some 20 to 40 million people annually in the United States, including 10 to 30% of adults and up to 40% of children. [1] Allergic rhinitis is a chronic inflammatory disease of the airways that can diminish quality of life. Allergic rhinitis is a type 1 hypersensitivity reaction of primarily nasal mucosa to allergens. [2] It is an inflammatory disease of rhino-ocular mucosa mediated by immunoglobulin E (IgE). Apart from classical known symptoms such as runny nose, post nasal drip, sneezing and nasal congestion, patients may also suffer from daytime fatigue, poor concentration, cognitive impairment, daytime sleepiness and sleep disturbance. [3] If severe, problems may include paranasal sinus pressure and pain or eustachian tube dysfunction described as ear popping and fullness. [1] According to the Allergic Rhinitis and its Impact on Asthma (ARIA) document, AR should be classified by chronicity (intermittent or persistent), and severity which is based on symptoms and quality of life (mild, or moderate/ severe). [4] The terms "seasonal" and "perennial" AR previously categorized AR by the clinically significant mediators which are responsible for recruitment, activation, and perpetuation of cellular infiltrate resulting in continued chronic nasal congestion during the late phase. [5] The latest-generation potent antihistamines such as desloratadine and levocetirizine have shown improved quality of life in allergic rhinitis studies. [6, 7] Montelukast, a leukotriene receptor antagonist, significantly improves daytime and nighttime symptoms in patients with allergic rhinitis and is now an approved therapy for allergic rhinitis. [8] This study compares desloratadine monotherapy and combination montelukast with desloratadine on quality of life in allergic rhinitis.
PATIENTS AND METHODS
The sample consisted of 40 patients referred to our polyclinic between May 2010 and September 2010. This study was approved by the Ethics Committee of Kartal Dr. Lutfi Kirdar Education and Research Hospital, and all participants signed an informed consent form.
Forty eligible patients (28 females, 12 males, mean age 29.8 years) were selected on the basis of age (17-44 years), a minimum two-year history of persistent allergic rhinitis, positive skin prick test to perennial allergens (grass, weed pollen and trees) and anterior rhinoscopy findings consistent with allergic rhinitis. Pregnant or lactating patients, smokers, patients with asthma requiring daily treatment and patients sensitized to seasonal allergens were excluded. Other exclusion criteria were upper respiratory tract infection during the six-week period preceding the study, severe illnesses, septal deviation, nasal polyps, acute or chronic rhinosinusitis, and any other condition that might affect nasal breathing or nocturnal sleep pattern. A six-week randomized, double-blind, cross-sectional study was designed:
A. Patients receiving desloratadine (5 mg), (n=20).
B. Patients receiving desloratadine (5 mg) montelukast (10 mg) combination therapy (n=20).
In group 1 and 2, the medication was administered once a day in the evening. Data was collected using the Allergic Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). Healthrelated quality of life was assessed using the RQLQ adapted for the Turkish population and filled by researchers via interviewing patients. This questionnaire contains 28 items in seven domains (activity limitation, sleep problems, nose symptoms, eye symptoms, non-nose noneye symptoms, practical problems and emotional function). Each item was scored from 0 (not troubling) to 6 (extremely troubling). [9, 10] Before and after the six week treatment the RQLQ was filled by researchers by interviewing patients. The responses of group 1 individuals were compared with group 2. Participants recorded their nighttime symptom scores before and after the treatment period. Results are presented for six-week treatment periods as a mean value of three individual scores, each rated from 0 to 3. The scores were as follows: difficulty falling asleep (0= not at all, 1= a little, 2= moderate, 3= very); nighttime awakening (0= not at all, 1= once, 2= more than once, 3= all night) and nasal congestion on awakening (0= none, 1= mild, noticeable but not troublesome, 2= moderate, noticeable and troublesome some of the time, 3= severe, troublesome most of the time/very troublesome some of the time). [9] 
Statistical analysis
Data were analyzed by the Wilcoxon signed rank test, sign test and marginal homogeneity test using IBM SPSS for Windows 19.0 version software program (IBM Corporation, Armonk, NY, USA). Alpha value greater than 0.05 was considered statistically significant.
RESULTS
In group 1 the mean RQLQ score was 3.17 before visit and 2.43 after six week treatment.
In group 2 the mean RQLQ score was 2.94 before visit and 1.73 after six weeks treatment (Table 1 and 2) . In other words, in group 1 and 2 mean RQLQ scores before visit were 3.17 and 2.94, whereas after treatment, they were 2.43 and 1.73, respectively. When patient groups 1 and 2 were compared, there was a significant decrease in scores after treatment in group 2 Figure 1 ). 
DISCUSSION
Allergic rhinitis is the most common form of allergic disease, estimated to affect up to 20% of the population worldwide. [11] Persistent allergic rhinitis is an allergic inflammation of the upper respiratory tract due to a year-round encounter with allergens. [12] The pathophysiologic mechanism of allergic rhinitis is characterized by inflammation of the nasal mucous membranes as a result of a complex response to nasal allergen exposure. These include the high numbers of inflammatory cells such as mast cells and eosinophils in the airway; when activated on exposure to airborne allergens they undergo degranulation and release inflammatory substances, including cysteinyl leukotrienes, histamine, prostaglandin D2, and kinins. [13] Although, the symptoms of perennial allergic rhinitis which include nasal congestion, rhinorrhea, pruritis, are not lifethreatening, breathing through the mouth may cause difficulties in falling asleep, nighttime awakening, snoring, somnolence, impaired mood, poor memory and decreased productivity at school and work.
The management of allergic rhinitis includes environmental control measures and pharmacotherapy.
Pharmacotherapy includes oral and intranasal H1 antihistamines, intranasal corticosteroids, oral and intranasal decongestants, intranasal anticholinergics, intranasal cromolyn and leukotriene receptor antagonists. None of the guidelines recommend oral first-generation antihistamines as part of treatment for AR. Second generation H1 antihistamines are in general recommended for mild to moderate disease as first line therapy, but not when treating nasal congestion. Oral decongestants are indicated in combination with oral antihistamines for nasal congestion, but patients should be monitored for serious side effects. [14] Topically applied intranasal decongestants should be limited in use to less than 10 days because of rhinitis medicamentosa, which is rebound swelling of the nasal membranes or drug induced rhinitis. [15, 16] Intranasal corticosteroids are often required in moderate to severe disease and are effective in reducing all symptoms of allergic rhinitis in addition to eye symptoms associated with allergic conjunctivitis. [17, 18] Leukotriene levels are increased in the early as well as the late phase of the allergic reaction. Nasal insufflation studies show that both leukotriene C4 (LTC4) and leukotriene D4 (LTD4) induce an increase in nasal mucosal blood flow and nasal airway resistance. [19] [20] [21] Montelukast is an orally active, highly selective cysteinyl leukotriene type-1 receptor antagonist of leukotreine D4, with affinities approximately two-fold greater than the natural ligand. It is rapidly absorbed, achieving peak plasma concentration (Cmax) in three to four hours and with a mean bioavailability of 64% following a 10 mg oral administration. Montelukast is well tolerated and has a safety profile similar in pediatric and adult populations.
Optimal pharmacotherapy must not only control symptoms but also improve patients' quality of life.
The improvement in quality of life depends mainly on the reduction of nasal obstruction, as nasal blockage is a crucial symptom in persistent allergic rhinitis that leads to sleep impairment and subsequent daytime somnolence, fatigue, and reduced productivity.
The efficacy of montelukast in the treatment of AR has been studied quite extensively over the past few years as monotherapy, combined with a second generation antihistamine, and with or without intranasal corticosteroids. [22] [23] [24] [25] [26] In our study, we compared the effects of desloratadine and desloratadine plus montelukast combination therapy on quality of life. Symptomatic patients were treated for six weeks with either desloratadine or desloratadine plus montelukast combination therapy.
In three reported studies, statistically significant endpoints in symptom scores were compared with placebo included daytime nasal symptoms scores, daytime eye symptom scores, nighttime symptom scores, and composite symptom scores. Nighttime symptoms (difficulty falling asleep, nighttime awakenings, and congestion upon awaking) appeared to have a better response with montelukast compared with antihistamines. [23, 24, 26] In our study, there was no statistically significant difference observed in emotional symptoms, non-eye/nose symptoms, difficulty to fall asleep and nighttime awakening in the desloratadine group. Whereas in the desloratadine plus montelukast combined group, even though there was no difference in non-nose/eye and emotional symptoms, there was a statistically significant difference in sleep related symptoms. In both groups there was significant improvement in eye and nasal symptoms as well as practical problems and activities.
The results of our study demonstrate that desloratadine plus montelukast combined therapy results in significant improvement in the quality of life of patients suffering from persistent allergic rhinitis. The benefits of the desloratadine plus montelukast combined preparation were evident in most domains measured by RQLQ, specifically in nasal symptoms, eye symptoms, practical problems and activity limitations.
In our study the 0-3 point scale nighttime symptoms questionnaire was also evaluated. Group 2 had significantly improved nighttime symptoms scores. A significant improvement over baseline was observed in both groups 1 and 2 but patients treated with desloratadine plus montelukast combination therapy had a more significant benefit.
These results agree with those of previous studies, which show that monotherapy with montelukast [8] desloratadine [27] or levocetirizine [28] [29] [30] produces greater improvement in quality of life than placebo in patients affected by persistent and/or perennial allergic rhinitis.
Ciebiada et al. [31] demonstrated that montelukast was as efficacious in the improvement of nasal congestion as desloratadine or levocetirizine, and that it was more efficacious than placebo. Furthermore, combination therapy was more effective than monotherapy with montelukast alone and more effective than monotherapy with montelukast or desloratadine. Their study showed that combination therapy with montelukast and an antihistamine may have a positive impact on persistent allergic rhinitis and improve quality of life and nighttime symptoms. [31] The improvement in nasal symptoms, eye symptoms, practical problems and activity limitations were nearly the same in patients treated with desloratadine and desloratadine plus montelukast combination therapy. Sleep symptom scores significantly decreased in patients treated with desloratadine plus montelukast combination therapy.
In conclusion, desloratadine plus montelukast combination therapy gave additional benefits in comparison to desloratadine alone and could be considered for patients whose quality of life is impaired by persistent allergic rhinitis. This study showed that desloratadine plus montelukast combination therapy has a considerable impact on quality of life, especially night symptoms.
